孟鲁司特钠与氢化可的松琥珀酸钠联合在小儿喘息性支气管炎中的应用分析

目的：探讨小儿喘息性支气管炎（PAB）应用孟鲁司特钠与氢化可的松琥珀酸钠联合治疗的临床效果。方法：选取某院2014年1月-2016年1月收治的114例喘息性支气管炎患儿，随机均分为2组。对照组：常规治疗+氢化可的松琥珀酸钠静脉滴注；观察组：在对照组基础上联合孟鲁司特钠口服。记录比较2组患者湿啰音、哮鸣音、喘息及咳嗽等临床症状与体征消失时间，治疗前后肿瘤坏死因子-α（TNF-α）、免疫球蛋白E（IgE）白细胞介素-6（IL-6）及白细胞介素-8（IL-8）水平，临床疗效与治疗结束后3个月内复发情况，以及治疗期间不良反应。结果：观察组湿啰音、哮鸣音、喘息及咳嗽等症状与体征消失时间均显著短于对照组（P<0.01）；与治疗前比较，治疗后2组炎症因子TNF-α、IgE、IL-6 及IL-8水平均显著改善（P<0.01），且观察组改善幅度更为显著（P<0.01）；观察组总有效率、复发率依次为96.49%，5.26%，均显著优于对照组的84.21%，17.54%（P<0.05）；2组不良反应比较，差异无统计学意义（P>0.05）。结论：PAB应用孟鲁司特钠与氢化可的松琥珀酸钠联合治疗能短期内控制患儿症状，改善炎症因子水平，复发率低，疗效切实，安全性高，具有较高临床参考价值。

Application of montelukast sodium combined with hydrocortisone sodium succinate in treatment of pediatric asthmatic bronchitis

OBJECTIVE To explore the clinical effect of the combination therapy of montelukast sodium with hydrocortisone sodium succinate in the treatment of pediatric asthmatic bronchitis (PAB).METHODS A total of 114 cases of asthmatic bronchitis treated in our hospital from January 2014 to January 2016 were selected and randomly divided into two groups.Patients in the control group received conventional treatment plus intravenous injection of hydrocortisone sodium succinate.Based on therapy in control group,montelukast sodium was added to patients in observation group.Wet rales,wheezing sound,breathing,coughing,etc.and disappeared times of signs,tumor necrosis factor-α (TNF-α),immunoglobulin E (IgE),interleukin-6 (IL-6) and interleukin-8 (IL-8),clinical efficacy and recurrence within 3 months,adverse reactions during treatment were compared between two groups.RESULTS Wet rales,wheezing,wheezing,cough and disappeared times of signs in observation group were all significantly less than those of control group (P<0.01).Compared with those before treatment,TNF-α,IgE,IL-6 and IL-8 significantly improved (P<0.01) after treatment,especially significant in observation group (P<0.01).The total effective rate and recurrence rate in observation group were respectively 96.49% and 5.26%,significantly higher than 84.21% and 17.54% in control group (P<0.05).The adverse reactions of the two groups were compared without statistical significance observed (P>0.05).CONCLUSION The combination of montelukast sodium and hydrocortisone sodium succinate can control symptoms of PAB in children and improve the level of inflammatory factor.This combined therapy has low recurrence rate,real effect,high safety and high clinical value.